JAK-3 inhibitors for treating allergic disorders

A method for treating asthma comprising administering to a patient a therapeutically effective amount of a compound of formula:

• 14
• wherein
• X is HN, R11N, S, O, CH2, or R11CH;
• R11 is (C1-C4)alkyl, or (C1-C4)alkanoyl;
• R1-R8 are each independently hydrogen, hydroxy, mercapto, amino, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, or halo;
• R9-R10 are each independently hydrogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkanoyl or halo;
• or R9 and R10 together are methylenedioxy;
• or a pharmaceutically acceptable salt thereof;
• wherein two adjacent groups of R1-R5 together with the phenyl ring to which they are attached may optionally form a fused ring;
• and
• wherein the ring formed by the two adjacent groups of R1-R5 may optionally be substituted with hydroxy, mercapto, amino, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, or halo.

A method for treating allergic reaction comprising administering to a patient a therapeutically effective amount of a compound of formula:

• 15
• wherein
• X is HN, R11N, S, O, CH2, or R11CH;
• R11 is (C1-C4)alkyl, or (C1-C4)alkanoyl;
• R1-R8 are each independently hydrogen, hydroxy, mercapto, amino, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, or halo;
• R9-R10 are each independently hydrogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkanoyl or halo;
• or R9 and R10 together are methylenedioxy;
• or a pharmaceutically acceptable salt thereof;
• wherein two adjacent groups of R1-R5 together with the phenyl ring to which they are attached may optionally form a fused ring;
• and
• wherein the ring formed by the two adjacent groups of R1-R5 may optionally be substituted with hydroxy, mercapto, amino, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, or halo.

A method for inhibiting proinflamatory mediator release comprising administering to a patient a therapeutically effective amount of a compound of formula:

• 16
• wherein (I)
• X is HN, R11N, S, O, CH2, or R11CH;
• R11 is (C1-C4)alkyl, or (C1-C4)alkanoyl;
• R1-R8 are each independently hydrogen, hydroxy, mercapto, amino, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, or halo;
• R9-R10 are each independently hydrogen, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkanoyl or halo;
• or R9 and R10 together are methylenedioxy;
• or a pharmaceutically acceptable salt thereof;
• wherein two adjacent groups of R1-R5 together with the phenyl ring to which they are attached may optionally form a fused ring;
• and
• wherein the ring formed by the two adjacent groups of R1-R5 may optionally be substituted with hydroxy, mercapto, amino, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, or halo.